Drug intelligence / Profile preview

VB-124

Development stage: Preclinical
Lead developer: Variant Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral

Overview

VB-124 is a preclinical-stage monoclonal antibody being developed by Variant Bio for the treatment of muscle disorders. The drug was identified through Variant Bio's proprietary genomic discovery platform, which analyzes genetic data from diverse global populations to identify novel therapeutic targets with significant biological impact. While the specific molecular target of VB-124 remains confidential, the program is designed to address unmet medical needs in muscle-related pathologies using human genetic evidence as a foundation for therapeutic development.

Targets

MCT4 (Monocarboxylate transporter 4)

Beyond the preview

Go deeper on VB-124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB-124.

Explore the full profile